Development of Injectable Amniotic Membrane Matrix for Postmyocardial Infarction Tissue Repair

Jeffrey J.D. Henry, Lawrence Delrosario, Jun Fang, Sze Yue Wong, Qizhi Fang, Richard Sievers, Surya Kotha, Aijun Wang, Diana Farmer, Praneeth Janaswamy, Randall J. Lee, Song Li

Research output: Contribution to journalArticle

Abstract

Ischemic heart disease represents the leading cause of death worldwide. Heart failure following myocardial infarction (MI) is associated with severe fibrosis formation and cardiac remodeling. Recently, injectable hydrogels have emerged as a promising approach to repair the infarcted heart and improve heart function through minimally invasive administration. Here, a novel injectable human amniotic membrane (hAM) matrix is developed to enhance cardiac regeneration following MI. Human amniotic membrane is isolated from human placenta and engineered to be a thermoresponsive, injectable gel around body temperature. Ultrasound-guided injection of hAM matrix into rat MI hearts significantly improves cardiac contractility, as measured by ejection fraction (EF), and decrease fibrosis. The results of this study demonstrate the feasibility of engineering as an injectable hAM matrix and its efficacy in attenuating degenerative changes in cardiac function following MI, which may have broad applications in tissue regeneration.

Original languageEnglish (US)
Article number1900544
JournalAdvanced Healthcare Materials
DOIs
StateAccepted/In press - Jan 1 2019

Fingerprint

Amnion
Infarction
Repair
Tissue
Membranes
Injections
Myocardial Infarction
Regeneration
Fibrosis
Tissue regeneration
Hydrogels
Feasibility Studies
Body Temperature
Placenta
Myocardial Ischemia
Rats
Cause of Death
Gels
Heart Failure
Ultrasonics

Keywords

  • amniotic membranes
  • decellularization
  • hydrogels
  • myocardial infarctions

ASJC Scopus subject areas

  • Biomaterials
  • Biomedical Engineering
  • Pharmaceutical Science

Cite this

Henry, J. J. D., Delrosario, L., Fang, J., Wong, S. Y., Fang, Q., Sievers, R., ... Li, S. (Accepted/In press). Development of Injectable Amniotic Membrane Matrix for Postmyocardial Infarction Tissue Repair. Advanced Healthcare Materials, [1900544]. https://doi.org/10.1002/adhm.201900544

Development of Injectable Amniotic Membrane Matrix for Postmyocardial Infarction Tissue Repair. / Henry, Jeffrey J.D.; Delrosario, Lawrence; Fang, Jun; Wong, Sze Yue; Fang, Qizhi; Sievers, Richard; Kotha, Surya; Wang, Aijun; Farmer, Diana; Janaswamy, Praneeth; Lee, Randall J.; Li, Song.

In: Advanced Healthcare Materials, 01.01.2019.

Research output: Contribution to journalArticle

Henry, JJD, Delrosario, L, Fang, J, Wong, SY, Fang, Q, Sievers, R, Kotha, S, Wang, A, Farmer, D, Janaswamy, P, Lee, RJ & Li, S 2019, 'Development of Injectable Amniotic Membrane Matrix for Postmyocardial Infarction Tissue Repair', Advanced Healthcare Materials. https://doi.org/10.1002/adhm.201900544
Henry, Jeffrey J.D. ; Delrosario, Lawrence ; Fang, Jun ; Wong, Sze Yue ; Fang, Qizhi ; Sievers, Richard ; Kotha, Surya ; Wang, Aijun ; Farmer, Diana ; Janaswamy, Praneeth ; Lee, Randall J. ; Li, Song. / Development of Injectable Amniotic Membrane Matrix for Postmyocardial Infarction Tissue Repair. In: Advanced Healthcare Materials. 2019.
@article{50a02a47eaab463b859014ebce353648,
title = "Development of Injectable Amniotic Membrane Matrix for Postmyocardial Infarction Tissue Repair",
abstract = "Ischemic heart disease represents the leading cause of death worldwide. Heart failure following myocardial infarction (MI) is associated with severe fibrosis formation and cardiac remodeling. Recently, injectable hydrogels have emerged as a promising approach to repair the infarcted heart and improve heart function through minimally invasive administration. Here, a novel injectable human amniotic membrane (hAM) matrix is developed to enhance cardiac regeneration following MI. Human amniotic membrane is isolated from human placenta and engineered to be a thermoresponsive, injectable gel around body temperature. Ultrasound-guided injection of hAM matrix into rat MI hearts significantly improves cardiac contractility, as measured by ejection fraction (EF), and decrease fibrosis. The results of this study demonstrate the feasibility of engineering as an injectable hAM matrix and its efficacy in attenuating degenerative changes in cardiac function following MI, which may have broad applications in tissue regeneration.",
keywords = "amniotic membranes, decellularization, hydrogels, myocardial infarctions",
author = "Henry, {Jeffrey J.D.} and Lawrence Delrosario and Jun Fang and Wong, {Sze Yue} and Qizhi Fang and Richard Sievers and Surya Kotha and Aijun Wang and Diana Farmer and Praneeth Janaswamy and Lee, {Randall J.} and Song Li",
year = "2019",
month = "1",
day = "1",
doi = "10.1002/adhm.201900544",
language = "English (US)",
journal = "Advanced healthcare materials",
issn = "2192-2640",
publisher = "John Wiley and Sons Ltd",

}

TY - JOUR

T1 - Development of Injectable Amniotic Membrane Matrix for Postmyocardial Infarction Tissue Repair

AU - Henry, Jeffrey J.D.

AU - Delrosario, Lawrence

AU - Fang, Jun

AU - Wong, Sze Yue

AU - Fang, Qizhi

AU - Sievers, Richard

AU - Kotha, Surya

AU - Wang, Aijun

AU - Farmer, Diana

AU - Janaswamy, Praneeth

AU - Lee, Randall J.

AU - Li, Song

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Ischemic heart disease represents the leading cause of death worldwide. Heart failure following myocardial infarction (MI) is associated with severe fibrosis formation and cardiac remodeling. Recently, injectable hydrogels have emerged as a promising approach to repair the infarcted heart and improve heart function through minimally invasive administration. Here, a novel injectable human amniotic membrane (hAM) matrix is developed to enhance cardiac regeneration following MI. Human amniotic membrane is isolated from human placenta and engineered to be a thermoresponsive, injectable gel around body temperature. Ultrasound-guided injection of hAM matrix into rat MI hearts significantly improves cardiac contractility, as measured by ejection fraction (EF), and decrease fibrosis. The results of this study demonstrate the feasibility of engineering as an injectable hAM matrix and its efficacy in attenuating degenerative changes in cardiac function following MI, which may have broad applications in tissue regeneration.

AB - Ischemic heart disease represents the leading cause of death worldwide. Heart failure following myocardial infarction (MI) is associated with severe fibrosis formation and cardiac remodeling. Recently, injectable hydrogels have emerged as a promising approach to repair the infarcted heart and improve heart function through minimally invasive administration. Here, a novel injectable human amniotic membrane (hAM) matrix is developed to enhance cardiac regeneration following MI. Human amniotic membrane is isolated from human placenta and engineered to be a thermoresponsive, injectable gel around body temperature. Ultrasound-guided injection of hAM matrix into rat MI hearts significantly improves cardiac contractility, as measured by ejection fraction (EF), and decrease fibrosis. The results of this study demonstrate the feasibility of engineering as an injectable hAM matrix and its efficacy in attenuating degenerative changes in cardiac function following MI, which may have broad applications in tissue regeneration.

KW - amniotic membranes

KW - decellularization

KW - hydrogels

KW - myocardial infarctions

UR - http://www.scopus.com/inward/record.url?scp=85075745449&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85075745449&partnerID=8YFLogxK

U2 - 10.1002/adhm.201900544

DO - 10.1002/adhm.201900544

M3 - Article

C2 - 31778043

AN - SCOPUS:85075745449

JO - Advanced healthcare materials

JF - Advanced healthcare materials

SN - 2192-2640

M1 - 1900544

ER -